Receptor-Mediated Delivery of CRISPR-Cas9 Endonuclease for Cell-Type-Specific Gene Editing
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
CRISPR-Cas RNA-guided endonucleases hold great promise for disrupting or correcting genomic sequences through site-specific DNA cleavage and repair. However, the lack of methods for cell- and tissue-selective delivery currently limits both research and clinical uses of these enzymes. We report the design and in vitro evaluation of S. pyogenes Cas9 proteins harboring asialoglycoprotein receptor ligands (ASGPrL). In particular, we demonstrate that the resulting ribonucleoproteins (Cas9-ASGPrL RNP) can be engineered to be preferentially internalized into cells expressing the corresponding receptor on their surface. Uptake of such fluorescently labeled proteins in liver-derived cell lines HEPG2 (ASGPr+) and SKHEP (control; diminished ASGPr) was studied by live cell imaging and demonstrates increased accumulation of Cas9-ASGPrL RNP in HEPG2 cells as a result of effective ASGPr-mediated endocytosis. When uptake occurred in the presence of a peptide with endosomolytic properties, we observed receptor-facilitated and cell-type specific gene editing that did not rely on electroporation or the use of transfection reagents. Overall, these in vitro results validate the receptor-mediated delivery of genome-editing enzymes as an approach for cell-selective gene editing and provide a framework for future potential applications to hepatoselective gene editing in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This delivery mode can reduce possible off-target mutations relative to delivering Cas9-encoding DNA or mRNA due to the short half-life of RNPs 76,85-87 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [87]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Self-citationHigh-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Kim, S., Kim, D., Cho, S. W., Kim, J., & Kim, J.-S. (2014) · Genome Research · doi:10.1101/gr.171322.113 · Cited by 1,856
Endosomal escape pathways for delivery of biologicals
Varkouhi, A. K., Scholte, M., Storm, G., & Haisma, H. J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.004 · Cited by 1,561
Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Zuris, J. A., Thompson, D. B., Shu, Y., Guilinger, J. P., Bessen, J. L., Hu, J. H., Maeder, M. L., Joung, J. K., Chen, Z.-Y., & Liu, D. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3081 · Cited by 1,460
Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery
Lin, S., Staahl, B. T., Alla, R. K., & Doudna, J. A. (2014) · eLife · doi:10.7554/elife.04766 · Cited by 1,189
Self-citationGene therapy clinical trials worldwide to 2012 – an update
Ginn, S. L., Alexander, I. E., Edelstein, M. L., Abedi, M. R., & Wixon, J. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2698 · Cited by 1,159
Nair, J. K., Willoughby, J. L. S., Chan, A., Charisse, K., Alam, M. R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel’in, A. V., Milstein, S., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505986a · Cited by 1,141
Overcoming cellular barriers for RNA therapeutics
Dowdy, S. F. (2017) · Nature Biotechnology · doi:10.1038/nbt.3802 · Cited by 1,139
Cited by
The promise and challenge of therapeutic genome editing
Doudna, J. A. (2020) · Nature · doi:10.1038/s41586-020-1978-5 · Cited by 1,126
Self-citationCRISPR technology: A decade of genome editing is only the beginning
Wang, J. Y., & Doudna, J. A. (2023) · Science · doi:10.1126/science.add8643 · Cited by 1,049
“Another challenge is preventing uptake and editing in off-target cells; this could be addressed by utilizing a targeting molecule, such as a single-chain variable fragment or glycoprotein, through conjugation to the CRISPR RNP (168).”
BackgroundInfluentialSelf-citationStrategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing
Zhang, S., Shen, J., Li, D., & Cheng, Y. (2021) · Theranostics · doi:10.7150/thno.47007 · Cited by 430
Liu, C., Wan, T., Wang, H., Zhang, S., Ping, Y., & Cheng, Y. (2019) · Science Advances · doi:10.1126/sciadv.aaw8922 · Cited by 396
Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment
Xu, X., Liu, C., Wang, Y., Koivisto, O., Zhou, J., Shu, Y., & Zhang, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113891 · Cited by 289
The delivery challenge: fulfilling the promise of therapeutic genome editing
van Haasteren, J., Li, J., Scheideler, O. J., Murthy, N., & Schaffer, D. V. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0565-5 · Cited by 285
Polymers for cytosolic protein delivery
Lv, J., Fan, Q., Wang, H., & Cheng, Y. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119358 · Cited by 262
Cell-Type-Specific CRISPR/Cas9 Delivery by Biomimetic Metal Organic Frameworks
Alyami, M. Z., Alsaiari, S. K., Li, Y., Qutub, S. S., Aleisa, F. A., Sougrat, R., Merzaban, J. S., & Khashab, N. M. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b11638 · Cited by 227
Schneider, A. F. L., Kithil, M., Cardoso, M. C., Lehmann, M., & Hackenberger, C. P. R. (2021) · Nature Chemistry · doi:10.1038/s41557-021-00661-x · Cited by 197
Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering
Hamilton, J. R., Tsuchida, C. A., Nguyen, D. N., Shy, B. R., McGarrigle, E. R., Sandoval Espinoza, C. R., Carr, D., Blaeschke, F., Marson, A., & Doudna, J. A. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109207 · Cited by 208
“Our group has previously demonstrated that directly modifying the Cas9 RNP with asialoglycoprotein receptor ligands promotes Cas9 RNP uptake into hepatic cell types in vitro (Rouet et al., 2018).”
BackgroundSelf-citationRational designs of in vivo CRISPR-Cas delivery systems
Xu, C.-F., Chen, G.-J., Luo, Y.-L., Zhang, Y., Zhao, G., Lu, Z.-D., Czarna, A., Gu, Z., & Wang, J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.11.005 · Cited by 184
Zhuang, J., Tan, J., Wu, C., Zhang, J., Liu, T., Fan, C., Li, J., & Zhang, Y. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa683 · Cited by 176
A Coordinative Dendrimer Achieves Excellent Efficiency in Cytosolic Protein and Peptide Delivery
Ren, L., Lv, J., Wang, H., & Cheng, Y. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201914970 · Cited by 170
Deng, S., Li, X., Liu, S., Chen, J., Li, M., Chew, S. Y., Leong, K. W., & Cheng, D. (2020) · Science Advances · doi:10.1126/sciadv.abb4005 · Cited by 169
“Several pH-buffering molecules, including imidazole, peptides, and polyethylenimine (PEI), have been introduced into nanoparticles to enhance lysosomal escape of Cas9 ( 25 , 27 ).”
Tietz, O., Cortezon‐Tamarit, F., Chalk, R., Able, S., & Vallis, K. A. (2022) · Nature Chemistry · doi:10.1038/s41557-021-00866-0 · Cited by 160
“38 Despite reports that cyclisation of CPPs can increase efficacy by up to two orders of magnitude, 39 cyclic trimers tri-cTat A and tri-cTat B did not show significantly improved uptake into the cytoplasm and nuclei of cells compared to linear Tat trimers.”
Non-viral delivery of the CRISPR/Cas system: DNA versus RNA versus RNP
Lin, Y., Wagner, E., & Lächelt, U. (2022) · Biomaterials Science · doi:10.1039/d1bm01658j · Cited by 154
Peptide-mediated delivery of CRISPR enzymes for the efficient editing of primary human lymphocytes
Foss, D. V., Muldoon, J. J., Nguyen, D. N., Carr, D., Sahu, S. U., Hunsinger, J. M., Wyman, S. K., Krishnappa, N., Mendonsa, R., Schanzer, E. V., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01032-2 · Cited by 149
Self-citationArtificial cells drive neural differentiation
Toparlak, Ö. D., Zasso, J., Bridi, S., Serra, M. D., Macchi, P., Conti, L., Baudet, M.-L., & Mansy, S. S. (2020) · Science Advances · doi:10.1126/sciadv.abb4920 · Cited by 137
“Once designed and decorated, such artificial cells could integrate within the host to controllably release extracellular factors and small molecules ( 26 ) or to deliver gene editing machinery ( 44 , 45 ).”
The Interaction of the Gut Microbiota with the Mucus Barrier in Health and Disease in Human
Corfield, A. P. (2018) · Microorganisms · doi:10.3390/microorganisms6030078 · Cited by 133
“The binding of the receptor to the cell surface, uptake through endocytosis, endosomal escape through endosome acidification and subsequent nuclear import has been achieved [284] and illustrates the power of this technology for application to mucosal surfaces.”
BackgroundMethodA review on biological and biomimetic materials and their applications
Kumar, N. S., Suvarna, R. P., Naidu, K. C. B., Banerjee, P., Ratnamala, A., & Manjunatha, H. (2020) · Applied Physics A · doi:10.1007/s00339-020-03633-z · Cited by 143
Wan, T., Niu, D., Wu, C., Xu, F.-J., Church, G., & Ping, Y. (2019) · Materials Today · doi:10.1016/j.mattod.2018.12.003 · Cited by 117
Carrier strategies boost the application of CRISPR/Cas system in gene therapy
Xu, Z., Wang, Q., Zhong, H., Jiang, Y., Shi, X., Yuan, B., Yu, N., Zhang, S., Yuan, X., Guo, S., et al. (2022) · Exploration · doi:10.1002/exp.20210081 · Cited by 109
Mashel, T. V., Tarakanchikova, Y. V., Muslimov, A. R., Zyuzin, M. V., Timin, A. S., Lepik, K. V., & Fehse, B. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120282 · Cited by 105
Abbasi, S., Uchida, S., Toh, K., Tockary, T. A., Dirisala, A., Hayashi, K., Fukushima, S., & Kataoka, K. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.02.026 · Cited by 98
CRISPR/Cas9 Delivery System Engineering for Genome Editing in Therapeutic Applications
Cheng, H., Zhang, F., & Ding, Y. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101649 · Cited by 108
Tang, Q., Liu, J., Jiang, Y. Y., Zhang, M., Mao, L., & Wang, M. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b17749 · Cited by 101
Liu, X., Zhao, Z., Wu, F., Chen, Y., & Yin, L. (2021) · Advanced Materials · doi:10.1002/adma.202108116 · Cited by 99
Biomaterials-mediated CRISPR/Cas9 delivery: recent challenges and opportunities in gene therapy
Dubey, A. K., & Mostafavi, E. (2023) · Frontiers in Chemistry · doi:10.3389/fchem.2023.1259435 · Cited by 103
“Gelatin nanoparticles equipped with Cas9 protein and guide RNA were shown to effectively transfer the elements to human embryonic kidney cells (HEK293T) and trigger gene editing, demonstrating the higher effectiveness with which gelatin nanoparticles can deliver CRISPR/Cas components to target cells (Rouet et al., 201…”
BackgroundTargeted nonviral delivery of genome editors in vivo
Tsuchida, C. A., Wasko, K. M., Hamilton, J. R., & Doudna, J. A. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2307796121 · Cited by 90
“Initial engineering efforts to endow cell targeting capa - bilities have involved fusion of Cas9 to a liver - specific ligand (132, 133) or a HER2 specific antibody fragment (134).”
BackgroundSelf-citationOptimizing synthetic nucleic acid and protein nanocarriers: The chemical evolution approach
Freitag, F., & Wagner, E. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.03.005 · Cited by 92
Genetic reprogramming for NK cell cancer immunotherapy with CRISPR/Cas9
Afolabi, L. O., Adeshakin, A. O., Sani, M. M., Bi, J., & Wan, X. (2019) · Immunology · doi:10.1111/imm.13094 · Cited by 80
Nucleic acid-based molecular computation heads towards cellular applications
Chen, L., Chen, W., Liu, G., Li, J., Lü, C., Li, J., Tan, W., & Yang, H. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01508c · Cited by 73
Ling, X., Chang, L., Chen, H., Gao, X., Yin, J., Zuo, Y., Huang, Y., Zhang, B., Hu, J., & Liu, T. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.09.021 · Cited by 73
Safe CRISPR: Challenges and Possible Solutions
Pineda, M., Lear, A., Collins, J. P., & Kiani, S. (2019) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.09.010 · Cited by 69
CRISPR Spherical Nucleic Acids
Huang, C., Han, Z., Evangelopoulos, M., & Mirkin, C. A. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c07913 · Cited by 68
Current status and prospect of ZIF-based materials for breast cancer treatment
Zeng, Y., Liao, D., Kong, X., Huang, Q., Zhong, M., Liu, J., Nezamzadeh‐Ejhieh, A., Pan, Y. H., & Song, H. (2023) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2023.113612 · Cited by 68
A Modular Ionophore Platform for Liver-Directed Copper Supplementation in Cells and Animals
Su, T. A., Shihadih, D. S., Cao, W., Detomasi, T. C., Heffern, M. C., Jia, S., Stahl, A., & Chang, C. J. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b08014 · Cited by 68
Protein‐Based Artificial Nanosystems in Cancer Therapy
Zhang, N., Mei, K., Guan, P., Hu, X., & Zhao, Y. (2020) · Small · doi:10.1002/smll.201907256 · Cited by 68
Delivery of CRISPR/Cas9 by Novel Strategies for Gene Therapy
Wang, L., Zheng, W., Liu, S., Li, B., & Jiang, X. (2019) · ChemBioChem · doi:10.1002/cbic.201800629 · Cited by 64
CRISPR–Cas9 delivery strategies for the modulation of immune and non-immune cells
Alsaiari, S. K., Eshaghi, B., Du, B., Kanelli, M., Li, G., Wu, X., Zhang, L., Chaddah, M., Lau, A., Yang, X., et al. (2024) · Nature Reviews Materials · doi:10.1038/s41578-024-00725-7 · Cited by 69
“Likewise, conjugating the asialoglycoprotein receptor ligand, which is highly expressed on hepatocytes, to Cas9 protein enabled the efficient delivery of Cas9–sgRNA ribonucleoprotein to the cytosol for cell-specific genome editing 180 .”
Non-viral strategies for delivering genome editing enzymes
Li, J., Røise, J. J., He, M., Das, R., & Murthy, N. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.09.004 · Cited by 68
Feng, S., Xie, X., Liu, J., Li, A., Wang, Q., Guo, D., Li, S., Li, Y., Wang, Z., Guo, T., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02139-z · Cited by 65
“Synthetic nano-delivery systems, for instance lipid NPs (LNPs) [97], polymeric NPs (PNPs) [138], and gold NPs (AuNPs) [139], showed significant potential in enhancing the editing efficacy for CRISPR/Cas systems.”
BackgroundEngineering designer beta cells with a CRISPR-Cas9 conjugation platform
Lim, D., Sreekanth, V., Cox, K. J., Law, B. K., Wagner, B. K., Karp, J. M., & Choudhary, A. (2020) · Nature Communications · doi:10.1038/s41467-020-17725-0 · Cited by 59
Lin, Y., Wilk, U., Pöhmerer, J., Hörterer, E., Höhn, M., Luo, X., Mai, H., Wagner, E., & Lächelt, U. (2022) · Small · doi:10.1002/smll.202205318 · Cited by 58
Intelligent nanotherapeutic strategies for the delivery of CRISPR system
Chen, C., Zhong, W., Du, S., Li, Y., Zeng, Y., Liu, K., Yang, J., Guan, X., & Han, X. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.12.013 · Cited by 59
Tissue-Specific Delivery of CRISPR Therapeutics: Strategies and Mechanisms of Non-Viral Vectors
Shalaby, K. E., Aouida, M., & El‐Agnaf, O. M. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197353 · Cited by 61
“…et al. 2019 [112] - Asialoglycoprotein receptor ligands, - Endosomolytic Peptide (ppTG21): GLFHALLHLLHSLWHLLLHA RNP ASGPrs on liver cells In vitro EMX1 Rouet et al. 2018 [113] Abbreviations: WNT10B (Wnt Family Member 10B); ASGPr (Asialoglycoprotein receptor); SORT (Selective ORgan Targeting),…”
BackgroundHepatocyte targeting via the asialoglycoprotein receptor
Ramírez-Cortés, F., & Ménová, P. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md00652f · Cited by 55
Du, W., Du, S., Dong, X., Bai, H., Jiang, J., Hao, S., Yang, F., Xiao, Q., Zhang, B., Ge, J., et al. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122000 · Cited by 55
A pH-Responsive Phase-Transition Polymer with High Serum Stability in Cytosolic Protein Delivery
Zhang, S., Lv, J., Gao, P., Feng, Q., Wang, H., & Cheng, Y. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c03031 · Cited by 59
Targeting cancer epigenetics with CRISPR-dCAS9: Principles and prospects
Rahman, M. M., & Tollefsbol, T. O. (2020) · Methods · doi:10.1016/j.ymeth.2020.04.006 · Cited by 56
“As hepatocytes are ASGPr rich, the selective Cas9 cargo designed by Rouet et al preferential entered into hepatocytes [143].”
BackgroundNanovesicle-Mediated Delivery Systems for CRISPR/Cas Genome Editing
Kim, D., Le, Q., Wu, Y., Park, J.-W., & Oh, Y. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121233 · Cited by 52
“A more recent study adapted this approach for targeted delivery of genome-editing components, tethering N-acetylgalactosamine to a Cas9/sgRNA ribonucleoprotein via a disulfide bond [122].”
BackgroundDirecting the Way—Receptor and Chemical Targeting Strategies for Nucleic Acid Delivery
Steffens, R. C., & Wagner, E. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03385-w · Cited by 53
“, antisense oligonucleotides [130–134] or Cas9 RNP complexes [135].”
BackgroundInfluentialProgrammable Molecular Scissors: Applications of a New Tool for Genome Editing in Biotech
Saha, S. K., Saikot, F. K., Rahman, M. S., Jamal, M. A. H. M., Rahman, S. M. K., Islam, S. M. R., & Kim, K. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.11.016 · Cited by 51
van Hees, M., Slott, S., Hansen, A. H., Kim, H. S., Ji, H. P., & Astakhova, K. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.06.003 · Cited by 47
Efficient Peptide-Mediated In Vitro Delivery of Cas9 RNP
Gustafsson, O., Rädler, J., Roudi, S., Lehto, T., Hällbrink, M., Lehto, T., Gupta, D., Andaloussi, S. E., & Nordin, J. Z. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060878 · Cited by 49
“The CPP-mediated delivery of Cas9 RNP has been explored before, however, previous attempts at RNP delivery using CPPs required large amounts of Cas9 and achieved low editing rates resulting in reduced therapeutic potential [10,25,26].”
BackgroundIlahibaks, N. F., Kluiver, T. A., de Jong, O. G., de Jager, S. C. A., Schiffelers, R. M., Vader, P., Peng, W. C., Lei, Z., & Sluijter, J. P. G. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12389 · Cited by 44
Khademi, Z., Ramezani, M., Alibolandi, M., Zirak, M. R., Salmasi, Z., Abnous, K., & Taghdisi, S. M. (2022) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2022.119691 · Cited by 45
CRISPR RNA-guided autonomous delivery of Cas9
Wilkinson, R. A., Martin, C. D., Nemudryi, A. A., & Wiedenheft, B. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0173-y · Cited by 48
Wu, C., Li, P., Fan, N., Han, J., Zhang, W., Zhang, W., & Tang, B. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b18410 · Cited by 43
Review of applications of CRISPR-Cas9 gene-editing technology in cancer research
Zhao, Z., Li, C., Tong, F., Deng, J., Huang, G., & Sang, Y. (2021) · Biological Procedures Online · doi:10.1186/s12575-021-00151-x · Cited by 46
“designed a Cas9 protein that carried the ASGPr ligand and formed a complex with sgRNA to deliver the CRISPR-Cas9 system specifically to liver cells [60].”
BackgroundHighly efficient CRISPR-mediated genome editing through microfluidic droplet cell mechanoporation
Kim, Y.-J., Yun, D., Lee, J. K., Jung, C., & Chung, A. J. (2024) · Nature Communications · doi:10.1038/s41467-024-52493-1 · Cited by 44
Nano-vectors for CRISPR/Cas9-mediated genome editing
Yang, P., Lee, A. Y.-T., Xue, J., Chou, S., Lee, C., Tseng, P., Zhang, T. X., Zhu, Y., Lee, J., Chiou, S., et al. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101482 · Cited by 42
The Application of CRISPR/Cas Systems for Antiviral Therapy
Baddeley, H. J. E., & Isalan, M. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.745559 · Cited by 45
“, 2020)), an innovative approach is the use of known receptor-ligand interactions to enable cell-type specific delivery (Rouet et al., 2018).”
BackgroundMolecular recognition with soft biomaterials
Clegg, J. R., & Peppas, N. A. (2019) · Soft Matter · doi:10.1039/c9sm01981b · Cited by 37
Öktem, M., de Jong, O. G., & Mastrobattista, E. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102500 · Cited by 36
Guo, S., Huang, Q., Wei, J., Wang, S., Wang, Y., Wang, L., & Wang, R. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101396 · Cited by 36
Song, N., Chu, Y., Li, S., Fan, X., Tang, J., Li, H., Tao, R., Li, F., Li, J., Yang, D., et al. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202306634 · Cited by 36
Peng, H., Le, C., Wu, J., Li, X., Zhang, H., & Le, X. C. (2020) · ACS Nano · doi:10.1021/acsnano.9b05276 · Cited by 36
Jakka, S. R., Govindaraj, V., & Mugesh, G. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201902347 · Cited by 34
Targeted Protein Internalization and Degradation by ENDosome TArgeting Chimeras (ENDTACs)
Nalawansha, D. A., Paiva, S.-L., Rafizadeh, D. N., Pettersson, M., Qin, L., & Crews, C. M. (2019) · ACS Central Science · doi:10.1021/acscentsci.9b00224 · Cited by 33
RetractedSynthetic Vehicles for Encapsulation and Delivery of CRISPR/Cas9 Gene Editing Machinery
Carboni, V., Maaliki, C., Alyami, M., Alsaiari, S. K., & Khashab, N. M. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201800085 · Cited by 36
Deng, F., Li, Y., Qiao, L., & Goldys, E. M. (2021) · Analytica Chimica Acta · doi:10.1016/j.aca.2021.339351 · Cited by 33
Precisely Targeted Nanoparticles for CRISPR-Cas9 Delivery in Clinical Applications
Liu, X., Gao, M., & Bao, J. (2025) · Nanomaterials · doi:10.3390/nano15070540 · Cited by 34
“…have reported that some ligands engineered on the nanoparticle surface can induce specific and efficient nanoparticle uptake via receptor-mediated endocytosis mechanisms, such as the folate receptor [19], low-density lipoprotein receptor (LDL-R) [89], and asialoglycoprotein receptor (ASGPr) [96].”
Directing Traffic: Halogen‐Bond‐Mediated Membrane Transport
Govindaraj, V., Ungati, H., Jakka, S. R., Bose, S., & Mugesh, G. (2019) · Chemistry - A European Journal · doi:10.1002/chem.201902243 · Cited by 34
Using CRISPR to enhance T cell effector function for therapeutic applications
Heeren, J. J. F. (2020) · Cytokine X · doi:10.1016/j.cytox.2020.100049 · Cited by 32
“This can be achieved by for instance receptor-mediated Cas9 uptake through the addition of fusion tags [83], lipid-based vector delivery [84,85], or cell-membrane penetration via the addition of cell-penetrating peptides [86–88].”
BackgroundQiu, M., Glass, Z., & Xu, Q. (2019) · Biomacromolecules · doi:10.1021/acs.biomac.9b00783 · Cited by 31
Smart Strategies for Precise Delivery of CRISPR/Cas9 in Genome Editing
Hasanzadeh, A., Noori, H., Jahandideh, A., Moghaddam, N. H., Mousavi, S. M. K., Nourizadeh, H., Saeedi, S., Karimi, M., & Hamblin, M. R. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c01112 · Cited by 30
Targeted intracellular delivery of Cas13 and Cas9 nucleases using bacterial toxin-based platforms
Tian, S., Liu, Y., Appleton, E., Wang, H., Church, G. M., & Dong, M. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110476 · Cited by 31
“…peptides, and physical methods such as electroporation have been utilized to deliver Cas proteins, RNP, or mRNA-encoding CRISPR-Cas systems (Blanchard et al., 2021; Lino et al., 2018; Ramakrishna et al., 2014; Rouet et al., 2018; Shalaby et al., 2020; Yip, 2020; Zuris et al., 2015).”
Liu, B., He, X., Xu, C., Ren, X.-H., Zhuo, R., & Cheng, S. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b05772 · Cited by 30
Key considerations in designing CRISPR/Cas9-carrying nanoparticles for therapeutic genome editing
Xu, Y., Liu, R., & Dai, Z. (2020) · Nanoscale · doi:10.1039/d0nr05452f · Cited by 29
Xie, R., Wang, Y., & Gong, S. (2021) · Biomaterials Science · doi:10.1039/d1bm00558h · Cited by 28
Taharabaru, T., Yokoyama, R., Higashi, T., Mohammed, A. F. A., Inoue, M., Maeda, Y. K., Niidome, T., Onodera, R., & Motoyama, K. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b21667 · Cited by 27
Gene editing for inflammatory disorders
Ewart, D. T., Peterson, E. J., & Steer, C. J. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213454 · Cited by 26
Active Delivery of CRISPR System Using Targetable or Controllable Nanocarriers
Lyu, Y., Yang, C., Lyu, X., & Pu, K. (2021) · Small · doi:10.1002/smll.202005222 · Cited by 26
Multivalent Targeting of the Asialoglycoprotein Receptor by Virus‐Like Particles
Hincapie, R., Bhattacharya, S., Baksh, M. M., Sanhueza, C., Echeverri, E. S., Kim, H., Paunovska, K., Podilapu, A. R., Xu, M., Dahlman, J. E., et al. (2023) · Small · doi:10.1002/smll.202304263 · Cited by 25
Nature Inspired Delivery Vehicles for CRISPR‐Based Genome Editing
Clarissa, E. M., Karmacharya, M., Choi, H., Kumar, S., & Cho, Y. (2025) · Small · doi:10.1002/smll.202409353 · Cited by 30
Therapeutic application of the CRISPR system: current issues and new prospects
Lee, M., & Kim, S. (2019) · Human Genetics · doi:10.1007/s00439-019-02028-2 · Cited by 25
Heeren, J. J. F. (2022) · BioTech · doi:10.3390/biotech11030025 · Cited by 25
“Ligand fusion tags Cell-type specific Cells need to express receptor No [67,68]”
BackgroundSystems of Delivery of CRISPR/Cas9 Ribonucleoprotein Complexes for Genome Editing
Амирханов, Р. Н., & Stepanov, G. A. (2019) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162019060025 · Cited by 23
Shalaby, K. E., Aouida, M., Gupta, V., Abdesselem, H., & El‐Agnaf, O. M. A. (2022) · Biomaterials Science · doi:10.1039/d2bm00368f · Cited by 21
Rouet, R., & Christ, D. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00116 · Cited by 21
Self-citationVersatile modification of the CRISPR/Cas9 ribonucleoprotein system to facilitate in vivo application
Sun, B., Chen, H., & Gao, X. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.08.007 · Cited by 22
Sahu, S. U., Castro, M., Muldoon, J. J., Asija, K., Wyman, S. K., Krishnappa, N., de Oñate, L., Eyquem, J., Nguyen, D. N., & Wilson, R. C. (2025) · Nature Protocols · doi:10.1038/s41596-025-01154-8 · Cited by 19
“(xxvii) Remove the 15-mL tube from the magnetic stand and wash the beads with 1 mL of DPBS.”
InfluentialSelf-citationSong, N., Tao, R., Li, H., Zhang, R., Huang, Y., Zhang, L., Liu, Y., Yang, D., & Yao, C. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202500566 · Cited by 20
Blossom of CRISPR technologies and applications in disease treatment
Liu, H., Wang, L., & Luo, Y. (2018) · Synthetic and Systems Biotechnology · doi:10.1016/j.synbio.2018.10.003 · Cited by 21
Non-Viral CRISPR carriers: transient delivery with lasting effects
Lummerstorfer, M., & Lächelt, U. (2026) · Drug Delivery · doi:10.1080/10717544.2026.2614125 · Cited by 19
“Genome editing proteins provide sites for covalent conjugation of receptor ligands, (Rouet et al. 2018) cell-penetrating peptides (Ramakrishna et al. 2014) and polymers (Kang et al. 2017) or can be genetically engineered to contain cell-penetrating motifs (Staahl et al. 2017; Kim et al. 2018; Chen…”
CRISPR /Cas gene editing and delivery systems for cancer therapy
Li, Y., Zhou, S., Wu, Q., & Gong, C. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1938 · Cited by 20
A new era of genetic engineering for autoimmune and inflammatory diseases
Ewart, D. T., Peterson, E. J., & Steer, C. J. (2019) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2019.05.004 · Cited by 17
Lee, J. H., Kang, Y. K., Oh, E., Jeong, J., Im, S. H., Kim, D. K., Lee, H., Kim, S., Jung, K., & Chung, H. J. (2021) · Chemistry of Materials · doi:10.1021/acs.chemmater.1c02844 · Cited by 16
Engineering CRISPR-Cas9 RNA–Protein Complexes for Improved Function and Delivery
Rouet, R., de Oñate, L., Li, J., Murthy, N., & Wilson, R. C. (2018) · The CRISPR Journal · doi:10.1089/crispr.2018.0037 · Cited by 16
Self-citation
Metadata
- Authors
- Rouet, R., Thuma, B. A., Roy, M. D., Lintner, N. G., Rubitski, D. M., Finley, J. E., Wisniewska, H. M., Mendonsa, R., Hirsh, A., de Oñate, L., Compte Barrón, J., McLellan, T. J., Bellenger, J., Feng, X., Varghese, A., Chrunyk, B. A., Borzilleri, K., Hesp, K. D., Zhou, K., Ma, N., Tu, M., Dullea, R., McClure, K. F., Wilson, R. C., Liras, S., Mascitti, V., & Doudna, J. A.
- Affiliations
- QB3 (US)
- Pfizer (United States) (US)
- Lawrence Berkeley National Laboratory (US)
- Corresponding author
- Liras, Spiros
- Mascitti, Vincent
- Doudna, Jennifer A.
- ORCID
- Venue
- Journal of the American Chemical Society
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-04-18
- Volume
- 140
- Issue
- 21
- Pages
- 6596-6603
- ISSN
- 0002-7863 (ISSN-L)
- 1520-5126
- PMC
- PMC6002863
- OpenAlex
- W2801459452
- Cited by
- 163
- References
- 48
- Citations by year
- 2026: 14 · 2025: 13 · 2024: 15 · 2023: 16 · 2022: 22 · 2021: 21 · 2020: 24 · 2019: 26 · 2018: 12
- FWCI
- 7.38
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of the American Chemical Society (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Health and Medical Research Council (APP1090875)
- Pfizer (86059)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Keywords
- CRISPR/Cas9, asialoglycoprotein receptor, receptor-mediated delivery, ribonucleoprotein, endocytosis, hepatocytes, genome editing
- MeSH terms
- Gene Editing, Endonucleases, Humans, Protein Engineering, Molecular Structure, Cell Line, Tumor, Hep G2 Cells, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.